FDA Approves Baxter’s Clinolipid for Neonatal and Pediatric Use
Baxter, a global leader in nutrition therapy, announced the U.S. FDA’s approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) for use in pediatric patients, including preterm and term…
Astellas Highlights Breakthroughs in Oncology at 2024 ASCO Annual Meeting
Astellas Pharma Inc. will present new research from its innovative cancer therapies portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4.…
Q1 2024 Qualitative Report: Performance Aligns with Full-Year 2024 Projections
In its quarterly qualitative update, Lonza reported a softer Q1, with performance across H1 expected to align with the full-year 2024 trajectory. Lonza confirms its 2024 outlook, projecting flat sales…
First-quarter performance as expected
The Bayer Group’s performance in the first quarter of the year met expectations, according to CEO Bill Anderson. “First-quarter sales declined slightly versus the prior year. The Pharmaceuticals Division saw…
AC Immune and Takeda Enter Exclusive License Agreement for Amyloid Beta Immunotherapy in Alzheimer’s Disease
Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, global option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including…
Sanofi Boosts Biomanufacturing Investment by €1B in France
Sanofi, the largest private contributor to France’s health ecosystem security and independence, announced a €1 billion investment to expand bioproduction at its sites in Vitry-sur-Seine, Le Trait, and Lyon Gerland.…
AbbVie and Gilgamesh Partner to Develop Next-Gen Psychiatric Therapies
AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals have announced a collaboration and option-to-license agreement aimed at developing next-generation therapies for psychiatric disorders. This partnership combines AbbVie’s psychiatric expertise with Gilgamesh’s innovative…
Novo Nordisk’s Mim8 Shows Superior Bleeding Reduction in Hemophilia A: Frontier 2 Trial
Novo Nordisk announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a study involving 254 participants over 26 weeks. This open-label, randomized, controlled, multi-arm trial assessed the…
Global Analysis: Rise in Protein Drug Use in Hematology and Oncology Boosts Market Outlook (2023-2028)
The anticipated growth of the global PEGylated proteins market is significant, with projections indicating a rise from $10.2 billion in 2023 to $15.9 billion by 2028, reflecting a robust compound…
Be Biopharma Unveils Promising Preclinical Data on Novel B Cell Treatment for Hypophosphatasia
Be Biopharma, Inc. (“Be Bio”), a trailblazing company in the development of Engineered B Cell Medicines (BCMs), unveiled new preclinical findings today, showcasing the production of active ALP by a…
Gossamer Bio Reveals Inducement Grant Compliant with Nasdaq Listing Rule 5635(c)(4)
A clinical-stage biopharmaceutical company, specializing in the advancement and market introduction of seralutinib for the management of pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD),…
Financial Performance Update: Revelation Biosciences, Inc. for Q1 2024
Revelation Biosciences, Inc. (NASDAQ: REVB), a clinical-stage life sciences firm dedicated to leveraging trained immunity for disease prevention and treatment, released its financial results for the three months ending March…